0
views
0
recommends
+1 Recommend
0 collections
    0
    shares
      • Record: found
      • Abstract: found
      • Article: found
      Is Open Access

      The potential of broadly neutralizing antibodies for HIV prevention

      research-article

      Read this article at

      Bookmark
          There is no author summary for this article yet. Authors can add summaries to their articles on ScienceOpen to make them more accessible to a non-specialist audience.

          Related collections

          Most cited references14

          • Record: found
          • Abstract: found
          • Article: not found

          Cabotegravir for HIV Prevention in Cisgender Men and Transgender Women

          Safe and effective long-acting injectable agents for preexposure prophylaxis (PrEP) for human immunodeficiency virus (HIV) infection are needed to increase the options for preventing HIV infection.
            Bookmark
            • Record: found
            • Abstract: found
            • Article: not found

            Two Randomized Trials of Neutralizing Antibodies to Prevent HIV-1 Acquisition

            Whether a broadly neutralizing antibody (bnAb) can be used to prevent human immunodeficiency virus type 1 (HIV-1) acquisition is unclear.
              Bookmark
              • Record: found
              • Abstract: found
              • Article: not found

              Enhanced antibody half-life improves in vivo activity.

              Improved affinity for the neonatal Fc receptor (FcRn) is known to extend antibody half-life in vivo. However, this has never been linked with enhanced therapeutic efficacy. We tested whether antibodies with half-lives extended up to fivefold in human (h)FcRn transgenic mice and threefold in cynomolgus monkeys retain efficacy at longer dosing intervals. We observed that prolonged exposure due to FcRn-mediated enhancement of half-life improved antitumor activity of Fc-engineered antibodies in an hFcRn/Rag1(-/-) mouse model. This bridges the demand for dosing convenience with the clinical necessity of maintaining efficacy.
                Bookmark

                Author and article information

                Contributors
                hgelderb@fredhutch.org
                dbarouch@bidmc.harvard.edu
                Journal
                J Int AIDS Soc
                J Int AIDS Soc
                10.1002/(ISSN)1758-2652
                JIA2
                Journal of the International AIDS Society
                John Wiley and Sons Inc. (Hoboken )
                1758-2652
                17 May 2024
                May 2024
                : 27
                : 5 ( doiID: 10.1002/jia2.v27.5 )
                : e26257
                Affiliations
                [ 1 ] Vaccine and Infectious Disease Division Fred Hutchinson Cancer Center Seattle Washington USA
                [ 2 ] Department of Medicine University of Washington Seattle Washington USA
                [ 3 ] Beth Israel Deaconess Medical Center Boston Massachusetts USA
                Author notes
                [*] [* ] Corresponding authors: Huub C. Gelderblom, Fred Hutchinson Cancer Center, 1100 Fairview Ave N, Mail Stop M2‐B500, Seattle, WA 98109, USA. ( hgelderb@ 123456fredhutch.org )

                Dan H. Barouch, Beth Israel Deaconess Medical Center, E/CLS‐1043, 330 Brookline Avenue, Boston, MA 02215, USA. ( dbarouch@ 123456bidmc.harvard.edu )

                Author information
                https://orcid.org/0000-0002-2179-2436
                https://orcid.org/0000-0001-5127-4659
                Article
                JIA226257
                10.1002/jia2.26257
                11100278
                38757844
                a77fe0d6-f2ac-4cb2-97ce-f683ef18c37e
                © 2024 The Authors. Journal of the International AIDS Society published by John Wiley & Sons Ltd on behalf of International AIDS Society.

                This is an open access article under the terms of the http://creativecommons.org/licenses/by/4.0/ License, which permits use, distribution and reproduction in any medium, provided the original work is properly cited.

                History
                : 11 April 2024
                : 16 April 2024
                Page count
                Figures: 0, Tables: 1, Pages: 3, Words: 1640
                Funding
                Funded by: NIH , doi 10.13039/100000002;
                Award ID: AI068614
                Award ID: AI128751
                Award ID: AI145801
                Award ID: AI149670
                Award ID: AI164556
                Award ID: AI169615
                Award ID: AI177687
                Categories
                Viewpoint
                Viewpoint
                Custom metadata
                2.0
                May 2024
                Converter:WILEY_ML3GV2_TO_JATSPMC version:6.4.3 mode:remove_FC converted:17.05.2024

                Infectious disease & Microbiology
                Infectious disease & Microbiology

                Comments

                Comment on this article